{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:50:31Z","timestamp":1793058631307,"version":"4.5.0"},"reference-count":232,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["AG042178"],"award-info":[{"award-number":["AG042178"]}]},{"name":"NIH","award":["AG047812"],"award-info":[{"award-number":["AG047812"]}]},{"name":"NIH","award":["NS205473"],"award-info":[{"award-number":["NS205473"]}]},{"name":"NIH","award":["AG060767"],"award-info":[{"award-number":["AG060767"]}]},{"name":"NIH","award":["AG069333"],"award-info":[{"award-number":["AG069333"]}]},{"name":"NIH","award":["AG066347"],"award-info":[{"award-number":["AG066347"]}]},{"name":"NIH","award":["AG079264"],"award-info":[{"award-number":["AG079264"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the leading cause of dementia in elderly people. Amyloid beta (A\u03b2) deposits and neurofibrillary tangles are the major pathological features in an Alzheimer\u2019s brain. These proteins are highly expressed in nerve cells and found in most tissues. Tau primarily provides stabilization to microtubules in the part of axons and dendrites. However, tau in a pathological state becomes hyperphosphorylated, causing tau dysfunction and leading to synaptic impairment and degeneration of neurons. This article presents a summary of the role of tau, phosphorylated tau (p-tau) in AD, and other tauopathies. Tauopathies, including Pick\u2019s disease, frontotemporal dementia, corticobasal degeneration, Alzheimer\u2019s disease, argyrophilic grain disease, progressive supranuclear palsy, and Huntington\u2019s disease, are the result of misprocessing and accumulation of tau within the neuronal and glial cells. This article also focuses on current research on the post-translational modifications and genetics of tau, tau pathology, the role of tau in tauopathies and the development of new drugs targeting p-tau, and the therapeutics for treating and possibly preventing tauopathies.<\/jats:p>","DOI":"10.3390\/ijms232112841","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T22:00:27Z","timestamp":1666735227000},"page":"12841","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":521,"title":["Phosphorylated Tau in Alzheimer\u2019s Disease and Other Tauopathies"],"prefix":"10.3390","volume":"23","author":[{"given":"Priyanka","family":"Rawat","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujala","family":"Sehar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasbir","family":"Bisht","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Selman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Culberson","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9560-9948","authenticated-orcid":false,"given":"P. Hemachandra","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"},{"name":"Nutritional Sciences Department, College Human Sciences, Texas Tech University, Lubbock, TX 79409, USA"},{"name":"Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"},{"name":"Department of Neurology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"},{"name":"Department of Public Health, Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"},{"name":"Department of Speech, Language, and Hearing Sciences, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101208","DOI":"10.1016\/j.arr.2020.101208","article-title":"Synaptic basis of Alzheimer\u2019s disease: Focus on synaptic amyloid beta, P-tau and mitochondria","volume":"65","author":"John","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.freeradbiomed.2021.07.013","article-title":"Defective mitophagy and synaptic degeneration in Alzheimer\u2019s disease: Focus on aging, mitochondria and synapse","volume":"172","author":"Morton","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer\u2019s disease: Genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sinsky, J., Pichlerova, K., and Hanes, J. (2021). Tau protein interaction partners and their roles in Alzheimer\u2019s disease and other tauopathies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179207"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbadis.2004.08.007","article-title":"Mutations causing neurodegenerative tauopathies","volume":"1739","author":"Goedert","year":"2005","journal-title":"Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.brainres.2011.07.052","article-title":"Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer\u2019s disease","volume":"1415","author":"Reddy","year":"2011","journal-title":"Brain Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/dvdy.24599","article-title":"ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins","volume":"247","author":"Ramkumar","year":"2018","journal-title":"Dev. Dyn."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/156720511795745401","article-title":"Mitochondria as a therapeutic target for aging and neurodegenerative diseases","volume":"8","author":"Reddy","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenarative tauopathies","volume":"24","author":"Lee","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/1521654032000114348","article-title":"The neuropathological spectrum of neurodegenerative tauopathies","volume":"55","author":"Tolnay","year":"2003","journal-title":"IUBMB Life"},{"key":"ref_11","first-page":"151979","article-title":"Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies?","volume":"2015","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"da Costa, P.J., Hamdane, M., Bu\u00e9e, L., and Martin, F. (2022). Tau mRNA Metabolism in Neurodegenerative Diseases: A Tangle Journey. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020241"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"246210","DOI":"10.6064\/2012\/246210","article-title":"The genetics of Alzheimer\u2019s disease","volume":"2012","author":"Barber","year":"2012","journal-title":"Scientifica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molmed.2007.12.002","article-title":"Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer\u2019s disease","volume":"14","author":"Reddy","year":"2008","journal-title":"Trends Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/bs.irn.2020.02.002","article-title":"APOE and metabolic dysfunction in Alzheimer\u2019s disease","volume":"154","author":"Johnson","year":"2020","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"630502","DOI":"10.3389\/fnins.2021.630502","article-title":"APOE and Alzheimer\u2019s disease: From lipid transport to physiopathology and therapeutics","volume":"15","author":"Husain","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-4-13","article-title":"The role of tau in neurodegeneration","volume":"4","author":"Gendron","year":"2009","journal-title":"Mol. Neurodegener."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejmech.2017.07.070","article-title":"Tau protein aggregation in Alzheimer\u2019s disease: An attractive target for the development of novel therapeutic agents","volume":"139","author":"Jouanne","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-015-0025-8","article-title":"Regulation of human MAPT gene expression","volume":"10","author":"Sergeant","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ijbiomac.2020.07.327","article-title":"Role of tau protein in Alzheimer\u2019s disease: The prime pathological player","volume":"163","author":"Muralidar","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3233\/JAD-180882","article-title":"Rbfox3\/NeuN regulates alternative splicing of tau exon 10","volume":"66","author":"Gu","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_22","first-page":"731526","article-title":"Structure and pathology of tau protein in Alzheimer disease","volume":"2012","author":"Kolarova","year":"2012","journal-title":"Int. J. Alzheimer\u2019s Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1002\/j.1460-2075.1990.tb07870.x","article-title":"Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization","volume":"9","author":"Goedert","year":"1990","journal-title":"EMBO J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","article-title":"The role of tau in Alzheimer\u2019s disease and related disorders","volume":"17","author":"Medeiros","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41467-022-30585-0","article-title":"Fluent molecular mixing of Tau isoforms in Alzheimer\u2019s disease neurofibrillary tangles","volume":"13","author":"Dregni","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1471-4159.2004.02155.x","article-title":"Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3\u03b2 (GSK3\u03b2) plays a critical role in regulating tau\u2019s ability to bind and stabilize microtubules","volume":"88","author":"Cho","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1326-6-39","article-title":"Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice","volume":"6","author":"Sengupta","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1021\/bi00198a017","article-title":"Domains of tau protein and interactions with microtubules","volume":"33","author":"Gustke","year":"1994","journal-title":"Biochemistry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12929-018-0457-x","article-title":"Untangling the Tauopathy for Alzheimer\u2019s disease and parkinsonism","volume":"25","author":"Chang","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neulet.2004.05.119","article-title":"The tau H2 haplotype is almost exclusively Caucasian in origin","volume":"369","author":"Evans","year":"2004","journal-title":"Neurosci. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/jmg.2005.031377","article-title":"Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration","volume":"42","author":"Pittman","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00401-017-1693-y","article-title":"Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia","volume":"133","author":"Yokoyama","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/hmg\/ddi241","article-title":"The H1c haplotype at the MAPT locus is associated with Alzheimer\u2019s disease","volume":"14","author":"Myers","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_34","first-page":"329","article-title":"Tau haplotypes regulate transcription and are associated with Parkinson\u2019s disease","volume":"55","author":"Kwok","year":"2004","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1093\/hmg\/ddi361","article-title":"High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy","volume":"14","author":"Rademakers","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3233\/JAD-2010-101011","article-title":"The effect of MAPT H1 and APOE \u03b54 on transition from mild cognitive impairment to dementia","volume":"22","author":"Samaranch","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1508","article-title":"A common inversion under selection in Europeans","volume":"37","author":"Stefansson","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/alzrt268","article-title":"Association of MAPT haplotypes with Alzheimer\u2019s disease risk and MAPT brain gene expression levels","volume":"6","author":"Allen","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000315901","article-title":"Recurrent inversion events at 17q21. 31 microdeletion locus are linked to the MAPT H2 haplotype","volume":"129","author":"Rao","year":"2010","journal-title":"Cytogenet. Genome Res."},{"key":"ref_40","unstructured":"Walsh, C. (2006). Posttranslational Modification of Proteins: Expanding Nature\u2019s Inventory, Roberts and Company Publishers."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"595532","DOI":"10.3389\/fneur.2020.595532","article-title":"Tau post-translational modifications: Dynamic transformers of tau function, degradation, and aggregation","volume":"11","author":"Alquezar","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101442","DOI":"10.1016\/j.jbc.2021.101442","article-title":"Post-translational modifications within tau paired helical filament nucleating motifs perturb microtubule interactions and oligomer formation","volume":"298","author":"Acosta","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1039\/D1SC00586C","article-title":"CHIP-mediated hyperubiquitylation of tau promotes its self-assembly into the insoluble tau filaments","volume":"12","author":"Kim","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_44","first-page":"346","article-title":"Post-translational modifications of tau protein","volume":"107","author":"Pevalova","year":"2006","journal-title":"Bratisl. Lek. Listy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fneur.2013.00083","article-title":"The importance of tau phosphorylation for neurodegenerative diseases","volume":"4","author":"Noble","year":"2013","journal-title":"Front. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1042\/BST0380967","article-title":"From tau phosphorylation to tau aggregation: What about neuronal death?","volume":"38","author":"Troquier","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/14789450.5.2.207","article-title":"Biochemistry of Tau in Alzheimer\u2019s disease and related neurological disorders","volume":"5","author":"Sergeant","year":"2008","journal-title":"Expert Rev. Proteom."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neuint.2010.12.023","article-title":"Post-translational modifications of tau protein: Implications for Alzheimer\u2019s disease","volume":"58","author":"Martin","year":"2011","journal-title":"Neurochem. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1582-4934.2007.00214.x","article-title":"Tau kinases and phosphatases","volume":"12","author":"Avila","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1523\/JNEUROSCI.4162-03.2004","article-title":"Phosphorylation of tau by fyn: Implications for Alzheimer\u2019s disease","volume":"24","author":"Lee","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Penke, B., Sz\u0171cs, M., and Bog\u00e1r, F. (2020). Oligomerization and conformational change turn monomeric \u03b2-amyloid and tau proteins toxic: Their role in Alzheimer\u2019s pathogenesis. Molecules, 25.","DOI":"10.3390\/molecules25071659"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1326-2-12","article-title":"Tau phosphorylation by GSK-3\u03b2 promotes tangle-like filament morphology","volume":"2","author":"Rankin","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-020-00648-9","article-title":"O-GlcNAcylation and its role in the immune system","volume":"27","author":"Chang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1021\/acschemneuro.8b00015","article-title":"Pharmacological inhibition of O-GlcNAcase enhances autophagy in brain through an mTOR-independent pathway","volume":"9","author":"Zhu","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschemneuro.2c00057","article-title":"O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and \u03b1-Synuclein Proteinopathies","volume":"13","author":"Permanne","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"ref_57","unstructured":"Yin, X., Li, Y., Fan, X., Huang, F., Qiu, Y., Zhao, C., Zhou, Z., Gu, Q., Xia, L., and Bao, J. (2022). SIRT1 deficiency increases O-GlcNAcylation of tau, mediating synaptic tauopathy. Mol. Psychiatry, 1\u201312. Available online: https:\/\/www.nature.com\/articles\/s41380-022-01689-2."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","article-title":"Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease","volume":"15","author":"Gong","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1586\/ern.09.104","article-title":"Mediators of tau phosphorylation in the pathogenesis of Alzheimer\u2019s disease","volume":"9","author":"Hanger","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"165584","DOI":"10.1016\/j.bbadis.2019.165584","article-title":"N-terminal tau truncation in the pathogenesis of Alzheimer\u2019s disease (AD): Developing a novel diagnostic and therapeutic approach","volume":"1866","author":"Amadoro","year":"2020","journal-title":"Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fnagi.2018.00027","article-title":"Relevance of phosphorylation and truncation of tau to the etiopathogenesis of Alzheimer\u2019s disease","volume":"10","author":"Zhou","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13812","DOI":"10.1074\/jbc.RA120.012587","article-title":"Truncation of Tau selectively facilitates its pathological activities","volume":"295","author":"Gu","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Friedrich, M.G., Skora, A., Hancock, S.E., Mitchell, T.W., Else, P.L., and Truscott, R.J. (2021). Tau is truncated in five regions of the normal adult human brain. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073521"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fncel.2015.00024","article-title":"Truncated tau deregulates synaptic markers in rat model for human tauopathy","volume":"9","author":"Jadhav","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/brain\/aws013","article-title":"Acetylated tau, a novel pathological signature in Alzheimer\u2019s disease and other tauopathies","volume":"135","author":"Irwin","year":"2012","journal-title":"Brain"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kim, M.-S., Mun, Y.-S., Lee, S.-E., Cho, W.-Y., Han, S.-H., Kim, D.-H., and Yoon, S.-Y. (Int. J. Neurosci., 2022). Tau acetylation at K280 regulates tau phosphorylation, Int. J. Neurosci., just-accepted.","DOI":"10.1080\/00207454.2022.2081165"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fmolb.2017.00056","article-title":"Lysine-directed post-translational modifications of tau protein in Alzheimer\u2019s disease and related tauopathies","volume":"4","author":"Kontaxi","year":"2017","journal-title":"Front. Mol. Biosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"786353","DOI":"10.3389\/fneur.2021.786353","article-title":"Tau Ubiquitination in Alzheimer\u2019s Disease","volume":"12","author":"Li","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddh083","article-title":"CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation","volume":"13","author":"Petrucelli","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12964-021-00732-z","article-title":"Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer\u2019s disease","volume":"19","author":"Balmik","year":"2021","journal-title":"Cell Commun. Signal."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"16586","DOI":"10.1073\/pnas.1417548111","article-title":"SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination","volume":"111","author":"Luo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1042\/BJ20140372","article-title":"Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity","volume":"462","author":"Funk","year":"2014","journal-title":"Biochem. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-2010-1243","article-title":"Phosphorylation-specific peptidyl-prolyl isomerization of neuronal cytoskeletal proteins by Pin1: Implications for therapeutics in neurodegeneration","volume":"19","author":"Rudrabhatla","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"a006247","DOI":"10.1101\/cshperspect.a006247","article-title":"Biochemistry and cell biology of tau protein in neurofibrillary degeneration","volume":"2","author":"Mandelkow","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.csbj.2014.09.011","article-title":"Cell-based models to investigate tau aggregation","volume":"12","author":"Lim","year":"2014","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.febslet.2006.05.029","article-title":"Truncated tau from sporadic Alzheimer\u2019s disease suffices to drive neurofibrillary degeneration in vivo","volume":"580","author":"Zilka","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s40478-021-01246-y","article-title":"Synaptic tau: A pathological or physiological phenomenon?","volume":"9","author":"Robbins","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/cn500148z","article-title":"The role of tau oligomers in the onset of Alzheimer\u2019s disease neuropathology","volume":"5","author":"DeRosa","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fneur.2013.00093","article-title":"Formation and propagation of tau oligomeric seeds","volume":"4","author":"Gerson","year":"2013","journal-title":"Front. Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2005.02.008","article-title":"Tau phosphorylation in Alzheimer\u2019s disease: Pathogen or protector?","volume":"11","author":"Lee","year":"2005","journal-title":"Trends Mol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"117253","DOI":"10.1016\/j.jns.2020.117253","article-title":"Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer\u2019s disease","volume":"421","author":"Bhatia","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"14203","DOI":"10.1021\/bi001876l","article-title":"Oxidative regulation of fatty acid-induced tau polymerization","volume":"39","author":"Gamblin","year":"2000","journal-title":"Biochemistry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"mbc. E21-11-0553","DOI":"10.1091\/mbc.E21-11-0553","article-title":"Long-term mitochondrial stress induces early steps of Tau aggregation by increasing reactive oxygen species levels and affecting cellular proteostasis","volume":"33","author":"Samluk","year":"2022","journal-title":"Mol. Biol. Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jnen\/59.10.880","article-title":"Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease","volume":"59","author":"Zhu","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0047-6374(01)00342-6","article-title":"Differential activation of neuronal ERK, JNK\/SAPK and p38 in Alzheimer disease: The \u2018two hit\u2019hypothesis","volume":"123","author":"Zhu","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1046\/j.1471-4159.2001.00046.x","article-title":"Activation and redistribution of c-jun N-terminal kinase\/stress activated protein kinase in degenerating neurons in Alzheimer\u2019s disease","volume":"76","author":"Zhu","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1046\/j.1471-4159.2000.0741587.x","article-title":"Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3\u03b2","volume":"74","author":"Reynolds","year":"2000","journal-title":"J. Neurochem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1083\/jcb.200108057","article-title":"Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress","volume":"156","author":"Stamer","year":"2002","journal-title":"J. Cell Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5\u2032-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1126\/science.282.5395.1914","article-title":"Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17","volume":"282","author":"Hong","year":"1998","journal-title":"Science"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.410430617","article-title":"Tau is a candidate gene for chromosome 17 frontotemporal dementia","volume":"43","author":"Poorkaj","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1073\/pnas.95.13.7737","article-title":"Mutation in the tau gene in familial multiple system tauopathy with presenile dementia","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.tips.2017.03.011","article-title":"A brief overview of tauopathy: Causes, consequences, and therapeutic strategies","volume":"38","author":"Orr","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00018-019-03349-1","article-title":"Mechanisms of secretion and spreading of pathological tau protein","volume":"77","author":"Brunello","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0531-5565(00)00114-5","article-title":"The molecular genetics of the tauopathies","volume":"35","author":"Lewis","year":"2000","journal-title":"Exp. Gerontol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1749-6632.2000.tb06906.x","article-title":"Molecular genetics of chromosome 17 tauopathies","volume":"920","author":"Hutton","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"590754","DOI":"10.3389\/fneur.2020.590754","article-title":"Tau filament self-assembly and structure: Tau as a therapeutic target","volume":"11","author":"Oakley","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fnagi.2020.00265","article-title":"Mechanisms of pathogenic tau and A\u03b2 protein spreading in Alzheimer\u2019s disease","volume":"12","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"590896","DOI":"10.3389\/fnmol.2020.590896","article-title":"New insights into drug discovery targeting tau protein","volume":"13","author":"Soeda","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pneurobio.2013.03.001","article-title":"Tau degradation: The ubiquitin\u2013proteasome system versus the autophagy-lysosome system","volume":"105","author":"Lee","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jalz.2016.06.006","article-title":"Therapeutic strategies for the treatment of tauopathies: Hopes and challenges","volume":"12","author":"Khanna","year":"2016","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0166-2236(96)80025-7","article-title":"The economics of neurite outgrowth\u2014The addition of new membrane to growing axons","volume":"19","author":"Futerman","year":"1996","journal-title":"Trends Neurosci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tins.2017.01.002","article-title":"Mitophagy and Alzheimer\u2019s disease: Cellular and molecular mechanisms","volume":"40","author":"Kerr","year":"2017","journal-title":"Trends Neurosci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1093\/hmg\/dds072","article-title":"Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer\u2019s disease neurons: Implications for mitochondrial dysfunction and neuronal damage","volume":"21","author":"Manczak","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","article-title":"Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration","volume":"68","author":"Hoover","year":"2010","journal-title":"Neuron"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: The therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1101\/lm.69204","article-title":"The cholinergic lesion of Alzheimer\u2019s disease: Pivotal factor or side show?","volume":"11","author":"Mesulam","year":"2004","journal-title":"Learn. Mem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/156720509787602843","article-title":"Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: Relevance to Alzheimer\u2019s disease","volume":"6","author":"Belarbi","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40478-018-0557-6","article-title":"Phosphorylation of different tau sites during progression of Alzheimer\u2019s disease","volume":"6","author":"Neddens","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fncel.2018.00338","article-title":"Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability","volume":"12","author":"Alonso","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.expneurol.2012.06.003","article-title":"Axonal degeneration in Alzheimer\u2019s disease: When signaling abnormalities meet the axonal transport system","volume":"246","author":"Kanaan","year":"2013","journal-title":"Exp. Neurol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1212\/WNL.45.4.788","article-title":"Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer\u2019s disease","volume":"45","author":"Seubert","year":"1995","journal-title":"Neurology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nm.3232","article-title":"The role of autophagy in neurodegenerative disease","volume":"19","author":"Nixon","year":"2013","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/brain\/aww021","article-title":"Is Huntington\u2019s disease a tauopathy?","volume":"139","author":"Gratuze","year":"2016","journal-title":"Brain"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/humu.20086","article-title":"The role of tau (MAPT) in frontotemporal dementia and related tauopathies","volume":"24","author":"Rademakers","year":"2004","journal-title":"Hum. Mutat."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/B978-0-12-802395-2.00025-0","article-title":"Tauopathies","volume":"145","author":"Kovacs","year":"2017","journal-title":"Handb. Clin. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","article-title":"Frontotemporal dementia","volume":"386","author":"Bang","year":"2015","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1192\/bjp.180.2.140","article-title":"Frontotemporal dementia","volume":"180","author":"Snowden","year":"2002","journal-title":"Br. J. Psychiatry"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1474-4422(05)70223-4","article-title":"Frontotemporal dementia","volume":"4","author":"Neary","year":"2005","journal-title":"Lancet Neurol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"f482","DOI":"10.1136\/bmj.f4827","article-title":"Frontotemporal dementia","volume":"347","author":"Warren","year":"2013","journal-title":"BMJ"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrneurol.2012.117","article-title":"Advances in understanding the molecular basis of frontotemporal dementia","volume":"8","author":"Rademakers","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Iyer, A., LaPointe, N.E., Zielke, K., Berdynski, M., Guzman, E., Barczak, A., Chodakowska-\u017bebrowska, M., Barcikowska, M., Feinstein, S., and \u017bekanowski, C. (2013). A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076409"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1750-3639.2007.00052.x","article-title":"Hereditary frontotemporal dementia caused by Tau gene mutations","volume":"17","author":"Spillantini","year":"2007","journal-title":"Brain Pathol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"a007476","DOI":"10.1101\/cshperspect.a007476","article-title":"Huntington\u2019s disease","volume":"3","author":"Finkbeiner","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1007\/s12035-021-02556-x","article-title":"Mitochondrial abnormalities and synaptic damage in huntington\u2019s disease: A focus on defective Mitophagy and mitochondria-targeted therapeutics","volume":"58","author":"Sawant","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.3233\/JAD-190851","article-title":"Role of phosphorylated Tau and glucose synthase kinase 3 beta in Huntington\u2019s disease progression","volume":"72","author":"Sawant","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"The role of tau in the pathological process and clinical expression of Huntington\u2019s disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3389\/fncel.2019.00574","article-title":"Altered levels and isoforms of tau and nuclear membrane invaginations in Huntington\u2019s disease","volume":"13","author":"Lucas","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/hmg\/ddu421","article-title":"Mutant huntingtin alters Tau phosphorylation and subcellular distribution","volume":"24","author":"Blum","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/brain\/awm305","article-title":"Argyrophilic grain disease","volume":"131","author":"Ferrer","year":"2008","journal-title":"Brain"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1590\/S1980-57642015DN91000002","article-title":"Argyrophilic grain disease: An underestimated tauopathy","volume":"9","author":"Rodriguez","year":"2015","journal-title":"Dement. Neuropsychol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0166-2236(98)01337-X","article-title":"Tau protein pathology in neurodegenerative diseases","volume":"21","author":"Spillantini","year":"1998","journal-title":"Trends Neurosci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1440-1789.2004.00591.x","article-title":"Argyrophilic grain disease: A late-onset dementia with distinctive features among tauopathies","volume":"24","author":"Tolnay","year":"2004","journal-title":"Neuropathology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00401-013-1080-2","article-title":"Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation","volume":"125","author":"Grinberg","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"Mackenzie","year":"2011","journal-title":"Neuron"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","volume":"390","author":"Hardiman","year":"2017","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fnins.2018.00259","article-title":"Phosphorylation of Threonine 175 Tau in the Induction of Tau Pathology in Amyotrophic Lateral Sclerosis\u2014Frontotemporal Spectrum Disorder (ALS-FTSD). A Review","volume":"12","author":"Moszczynski","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00005072-199602000-00004","article-title":"Specific pathological Tau protein variants characterize Pick\u2019s disease","volume":"55","author":"Delacourte","year":"1996","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/BF00688501","article-title":"Early Pick\u2019s disease","volume":"21","author":"Towfighi","year":"1972","journal-title":"Acta Neuropathol."},{"key":"ref_147","first-page":"559","article-title":"Filaments of Pick\u2019s bodies contain altered cytoskeletal elements","volume":"127","author":"Perry","year":"1987","journal-title":"Am. J. Pathol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(86)92212-9","article-title":"Filamentous aggregates in Pick\u2019s disease, progressive supranuclear palsy, and Alzheimer\u2019s disease share antigenic determinants with microtubule-associated protein, tau","volume":"328","author":"Pollock","year":"1986","journal-title":"Lancet"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/jnen\/60.12.1190","article-title":"Activation of the JNK\/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis","volume":"60","author":"Atzori","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s007020100016","article-title":"Phosphorylated mitogen-activated protein kinase (MAPK\/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK\/JNK-P), and calcium\/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies","volume":"108","author":"Ferrer","year":"2001","journal-title":"J. Neural Transm."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0197-4580(02)00029-5","article-title":"The p38 pathway is activated in Pick disease and progressive supranuclear palsy: A mechanistic link between mitogenic pathways, oxidative stress, and tau","volume":"23","author":"Hartzler","year":"2002","journal-title":"Neurobiol. Aging"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"24313","DOI":"10.1074\/jbc.271.40.24313","article-title":"Sounding the alarm: Protein kinase cascades activated by stress and inflammation","volume":"271","author":"Kyriakis","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0898-6568(97)00042-9","article-title":"Stress-activated protein kinases: Activation, regulation and function","volume":"9","author":"Paul","year":"1997","journal-title":"Cell. Signal."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: Clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1474-4422(02)00161-8","article-title":"Progressive supranuclear palsy: Where are we now?","volume":"1","author":"Burn","year":"2002","journal-title":"Lancet Neurol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ana.410180503","article-title":"Dopaminergic and cholinergic lesions in progressive supranuclear palsy","volume":"18","author":"Ruberg","year":"1985","journal-title":"Ann. Neurol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1750-3639.2001.tb00387.x","article-title":"Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick\u2019s disease, progressive supranuclear palsy and corticobasal degeneration","volume":"11","author":"Ferrer","year":"2001","journal-title":"Brain Pathol."},{"key":"ref_158","first-page":"427","article-title":"Progressive supranuclear palsy","volume":"54","author":"Tawana","year":"2001","journal-title":"Mol. Pathol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.parkreldis.2021.09.008","article-title":"Tau and MAPT genetics in tauopathies and synucleinopathies","volume":"90","author":"Leveille","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00401-013-1171-0","article-title":"Globular glial tauopathies (GGT): Consensus recommendations","volume":"126","author":"Ahmed","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","article-title":"Primary age-related tauopathy (PART): A common pathology associated with human aging","volume":"128","author":"Crary","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2018.07.215","article-title":"Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer\u2019s disease","volume":"15","author":"Bell","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jalz.2017.01.028","article-title":"Cognitive decline associated with pathological burden in primary age-related tauopathy","volume":"13","author":"Wolk","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S1474-4422(04)00936-6","article-title":"Corticobasal degeneration","volume":"3","author":"Mahapatra","year":"2004","journal-title":"Lancet Neurol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1093\/brain\/awr234","article-title":"Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome","volume":"134","author":"Kouri","year":"2011","journal-title":"Brain"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Grijalvo-Perez, A.M., and Litvan, I. (2014). Corticobasal Degeneration. Seminars in Neurology, Thieme Medical Publishers.","DOI":"10.1055\/s-0034-1381734"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00005072-199906000-00011","article-title":"Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau","volume":"58","author":"Bugiani","year":"1999","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/1531-8249(200012)48:6<939::AID-ANA17>3.0.CO;2-1","article-title":"A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies","volume":"48","author":"Yoshida","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000358761","article-title":"Chronic traumatic encephalopathy","volume":"28","author":"Omalu","year":"2014","journal-title":"Concussion"},{"key":"ref_170","first-page":"816069","article-title":"Chronic traumatic encephalopathy: A review","volume":"2012","author":"Saulle","year":"2012","journal-title":"Rehabil. Res. Pract."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bpa.12248","article-title":"The neuropathology of chronic traumatic encephalopathy","volume":"25","author":"McKee","year":"2015","journal-title":"Brain Pathol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.drudis.2018.11.005","article-title":"Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer\u2019s disease","volume":"24","author":"Pradeepkiran","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/JAD-2009-0933","article-title":"Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide A\u03b2 25\u201335: Involvement of lipid rafts","volume":"16","author":"Hernandez","year":"2009","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid \u03b2-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration","volume":"108","author":"Jin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1515\/REVNEURO.2008.19.6.383","article-title":"Caspase activation in Alzheimer\u2019s disease: Early to rise and late to bed","volume":"19","author":"Rohn","year":"2008","journal-title":"Rev. Neurosci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"10032","DOI":"10.1073\/pnas.1630428100","article-title":"Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer\u2019s disease","volume":"100","author":"Gamblin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.neurobiolaging.2009.06.005","article-title":"Endogenous A\u03b2 causes cell death via early tau hyperphosphorylation","volume":"32","author":"Amadoro","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1038\/ncomms9490","article-title":"Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer\u2019s disease brain","volume":"6","author":"Takeda","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrn2967","article-title":"Amyloid-\u03b2 and tau\u2014A toxic pas de deux in Alzheimer\u2019s disease","volume":"12","author":"Ittner","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fnins.2019.00735","article-title":"Targeting the synapse in Alzheimer\u2019s disease","volume":"13","author":"Jackson","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e21965","DOI":"10.1002\/syn.21965","article-title":"Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early A lzheimer\u2019s disease","volume":"71","author":"Pickett","year":"2017","journal-title":"Synapse"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"101529","DOI":"10.1016\/j.arr.2021.101529","article-title":"Deregulated mitochondrial microRNAs in Alzheimer\u2019s disease: Focus on synapse and mitochondria","volume":"73","author":"Gowda","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.npp.1301559","article-title":"Synaptic plasticity: Multiple forms, functions, and mechanisms","volume":"33","author":"Citri","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","article-title":"The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease","volume":"12","author":"Zetterberg","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"180138","DOI":"10.1098\/rsob.180138","article-title":"Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: An overview of induced pluripotent stem-cell-based disease models","volume":"8","author":"Taoufik","year":"2018","journal-title":"Open Biol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1177271920950319","DOI":"10.1177\/1177271920950319","article-title":"Fluid biomarkers for synaptic dysfunction and loss","volume":"15","author":"Camporesi","year":"2020","journal-title":"Biomark. Insights"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40035-021-00270-1","article-title":"The role of pathological tau in synaptic dysfunction in Alzheimer\u2019s diseases","volume":"10","author":"Wu","year":"2021","journal-title":"Transl. Neurodegener."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"15295","DOI":"10.1038\/ncomms15295","article-title":"Tau association with synaptic vesicles causes presynaptic dysfunction","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.018","article-title":"A role for tau at the synapse in Alzheimer\u2019s disease pathogenesis","volume":"76","author":"Pooler","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref_190","first-page":"464","article-title":"Tau oligomers: The toxic player at synapses in Alzheimer\u2019s disease","volume":"9","author":"Gerson","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1515\/tnsci-2015-0023","article-title":"Tau-mediated synaptic damage in Alzheimer\u2019s disease","volume":"6","author":"Jadhav","year":"2015","journal-title":"Transl. Neurosci."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"a005777","DOI":"10.1101\/cshperspect.a005777","article-title":"Synapses and Alzheimer\u2019s disease","volume":"4","author":"Sheng","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40478-019-0754-y","article-title":"Intersection of pathological tau and microglia at the synapse","volume":"7","author":"Vogels","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s40473-019-00179-0","article-title":"Mitochondrial dysfunction in Alzheimer\u2019s disease and progress in mitochondria-targeted therapeutics","volume":"6","author":"Flannery","year":"2019","journal-title":"Curr. Behav. Neurosci. Rep."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1471-4914(01)02173-6","article-title":"Evidence of oxidative damage in Alzheimer\u2019s disease brain: Central role for amyloid \u03b2-peptide","volume":"7","author":"Butterfield","year":"2001","journal-title":"Trends Mol. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3389\/fnins.2019.01444","article-title":"Interplay between mitochondrial oxidative disorders and proteostasis in Alzheimer\u2019s disease","volume":"13","author":"Alcain","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1126\/science.1219855","article-title":"Mitochondrial fission, fusion, and stress","volume":"337","author":"Youle","year":"2012","journal-title":"Science"},{"key":"ref_198","first-page":"136","article-title":"Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.3233\/JAD-2010-100339","article-title":"The Alzheimer\u2019s disease mitochondrial cascade hypothesis","volume":"20","author":"Swerdlow","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3389\/fphar.2019.00902","article-title":"Mitochondria as potential targets in Alzheimer disease therapy: An update","volume":"10","author":"Cenini","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fnagi.2020.00252","article-title":"Mitochondrial dysfunction and Alzheimer\u2019s disease: Role of microglia","volume":"12","author":"Agrawal","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Szabo, L., Eckert, A., and Grimm, A. (2020). Insights into disease-associated tau impact on mitochondria. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176344"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.13607","article-title":"Neuroinflammation: The devil is in the details","volume":"139","author":"DiSabato","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00005072-199702000-00004","article-title":"Microglial cell activation in aging and Alzheimer disease: Partial linkage with neurofibrillary tangle burden in the hippocampus","volume":"56","author":"DiPatre","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0006-8993(91)90783-R","article-title":"Microglia are associated with the extracellular neurofibrillary tangles of Alzheimer disease","volume":"558","author":"Cras","year":"1991","journal-title":"Brain Res."},{"key":"ref_206","first-page":"50","article-title":"Relationship between tau pathology and neuroinflammation in Alzheimer\u2019s disease","volume":"77","author":"Metcalfe","year":"2010","journal-title":"Mt. Sinai J. Med. A J. Transl. Pers. Med. A J. Transl. Pers. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.neuron.2009.08.039","article-title":"Immune activation in brain aging and neurodegeneration: Too much or too little?","volume":"64","author":"Lucin","year":"2009","journal-title":"Neuron"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1152\/physrev.00042.2016","article-title":"Physiology of astroglia","volume":"98","author":"Verkhratsky","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jnen\/nlx007","article-title":"Evaluating the patterns of aging-related tau astrogliopathy unravels novel insights into brain aging and neurodegenerative diseases","volume":"76","author":"Kovacs","year":"2017","journal-title":"J. Neuropatholgy Exp. Neurol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13024-017-0192-x","article-title":"Glial contributions to neurodegeneration in tauopathies","volume":"12","author":"Leyns","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1742-2094-7-56","article-title":"LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice","volume":"7","author":"Lee","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"572850","DOI":"10.3389\/fneur.2020.572850","article-title":"Astrocytes in tauopathies","volume":"11","author":"Reid","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"570045","DOI":"10.3389\/fnmol.2020.570045","article-title":"Tau protein and its role in blood\u2013brain barrier dysfunction","volume":"13","author":"Michalicova","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Majerova, P., Michalicova, A., Cente, M., Hanes, J., Vegh, J., Kittel, A., Kosikova, N., Cigankova, V., Mihaljevic, S., and Jadhav, S. (2019). Trafficking of immune cells across the blood-brain barrier is modulated by neurofibrillary pathology in tauopathies. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217216"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2009.01.013","article-title":"Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy","volume":"209","author":"Zilka","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40478-017-0488-7","article-title":"What is the evidence that tau pathology spreads through prion-like propagation?","volume":"5","author":"Mudher","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12974-018-1309-z","article-title":"The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer\u2019s disease","volume":"15","author":"Hopp","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","article-title":"Microglial activation and tau propagate jointly across Braak stages","volume":"27","author":"Pascoal","year":"2021","journal-title":"Nat. Med."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Medina, M. (2018). An overview on the clinical development of tau-based therapeutics. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041160"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","article-title":"A walk through tau therapeutic strategies","volume":"7","author":"Jadhav","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1179573520907397","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in Alzheimer disease: An update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2022). Delivery of Intravenously Administered Antibodies Targeting Alzheimer\u2019s Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020411"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"105010","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting A\u03b2 and tau in Alzheimer\u2019s disease","volume":"144","author":"Plotkin","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"11","DOI":"10.20517\/and.2022.16","article-title":"Tau-targeting therapy in Alzheimer\u2019s disease: Critical advances and future opportunities","volume":"2","author":"Guo","year":"2022","journal-title":"Ageing Neurodegener. Dis."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3389\/fnins.2018.00798","article-title":"Ten years of tau-targeted immunotherapy: The path walked and the roads ahead","volume":"12","author":"Novak","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and challenges for antisense oligonucleotide therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/alzrt125","article-title":"Ayurvedic medicinal plants for Alzheimer\u2019s disease: A review","volume":"4","author":"Rao","year":"2012","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14737175.2019.1596803","article-title":"Traditional Ayurvedic and herbal remedies for Alzheimer\u2019s disease: From bench to bedside","volume":"19","author":"Sharma","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"884345","DOI":"10.3389\/fnins.2022.884345","article-title":"Natural Therapeutics in Aid of Treating Alzheimer\u2019s Disease: A Green Gateway Toward Ending Quest for Treating Neurological Disorders","volume":"16","author":"Bhat","year":"2022","journal-title":"Front. Neurosci."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2481076","DOI":"10.1155\/2018\/2481076","article-title":"Ayurvedic medicine for the treatment of dementia: Mechanistic aspects","volume":"2018","author":"Farooqui","year":"2018","journal-title":"Evid.-Based Complementary Altern. Med."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4155\/fmc.12.124","article-title":"Natural products as a rich source of tau-targeting drugs for Alzheimer\u2019s disease","volume":"4","author":"Calcul","year":"2012","journal-title":"Future Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/12841\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:02:07Z","timestamp":1760144527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/12841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":232,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijms232112841"],"URL":"https:\/\/doi.org\/10.3390\/ijms232112841","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}